ArticleIntestinal Failure (New York, N.Y.)
Randomized prospective trial comparing mixed oil versus soybean oil lipid emulsion: A feasibility pilot study.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Mixed-oil (MO) intravenous lipid emulsions (ILEs) are increasingly used in adults receiving home parenteral nutrition (HPN), but prospective data from United States HPN programs remain limited. This feasibility pilot trial randomized adults newly initiated on HPN to MO versus soybean-oil (SO) ILE. The prespecified primary endpoint was change in total bilirubin over 12 weeks; secondary endpoints included feasibility, tolerance/safety, liver enzymes, C-reactive protein (CRP), and fatty acid profile. Methods: This was a pragmatic, single-center, blinded, randomized, prospective trial of adults newly initiated on HPN and expected to require HPN for more than 3 months. Participants were randomized to SO ILE or MO ILE. The standard HPN follow-up protocol was used to assess tolerance, complications, laboratory outcomes, and fatty acid profiles at baseline and through 12 weeks. Analyses included randomized participants with available data at each time point. Results: Twenty-two participants were randomized (SO ILE n = 11; MO ILE n = 11). Groups were similar in baseline demographic and PN macronutrient characteristics, and all participants had normal baseline liver enzymes and bilirubin. Total bilirubin, the primary endpoint, did not differ significantly between groups at weeks 4, 8, or 12 (week 12 median change 0 [IQR -0.1, 0.1] in SO ILE vs 0 [0, 0.1] in MO ILE; p = 0.96). No significant between-group differences were observed in liver enzymes or CRP. MO ILE was associated with significant increases in EPA and DHA by week 4 that were maintained through week 12, whereas SO ILE was not. Conclusion: In this feasibility pilot study, MO ILE was tolerated in United States adults newly initiated on HPN and produced the expected increase in EPA and DHA, with potential benefit in reduction of inflammation in the setting of inflammatory insult. Further multi-center trials are needed to confirm these findings and explore long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.